Protalex Inc (PRTX):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Protalex Inc (PRTX) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C12416
◆発行会社(調査会社):GlobalData
◆発行日:2018年12月
◆ページ数:19
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Protalex Inc (Protalex) is a biopharmaceutical company that develops drugs for the treatment of autoimmune and inflammatory diseases. The company offers treatment for a range of autoimmune diseases such as rheumatoid arthritis and immune thrombocytopenia. Its lead product candidate includes PRTX-100, a formulation of staphylococcal protein A, which is an immune modulating protein produced by staphylococcus aureus bacteria. Protalex’s product candidate binds human B-lymphocytes and macrophages to modulate immune processes that mediate inflammation in certain autoimmune diseases. The company provides low doses of PRTX-100, which are used in certain models of immune mediated inflammatory diseases. Protalex is headquartered in Florham Park, New Jersey, the US.

Protalex Inc (PRTX) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Protalex Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Protalex Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Protalex Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Protalex Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Protalex Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Protalex Inc, Pharmaceuticals & Healthcare, Deal Details 10
Equity Offering 10
Protalex Files Registration Statement for Public Offering of Shares 10
Protalex Files Registration Statement For Public Offering Of Shares For US$26 Million 11
Protalex Completes Private Placement Of Shares For US$2.8 Million 12
Debt Offering 13
Protalex Raise USD1.4 Million in Private Placement of Notes Due 2023 13
Protalex Inc – Key Competitors 14
Protalex Inc – Key Employees 15
Protalex Inc – Locations And Subsidiaries 16
Head Office 16
Recent Developments 17
Government and Public Interest 17
Oct 06, 2017: FDA awards 15 grants for clinical trials to stimulate product development for rare diseases 17
Appendix 19
Methodology 19
About GlobalData 19
Contact Us 19
Disclaimer 19

List of Tables
Protalex Inc, Pharmaceuticals & Healthcare, Key Facts, 2018 2
Protalex Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Protalex Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Protalex Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Protalex Inc, Deals By Therapy Area, 2012 to YTD 2018 8
Protalex Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Protalex Files Registration Statement for Public Offering of Shares 10
Protalex Files Registration Statement For Public Offering Of Shares For US$26 Million 11
Protalex Completes Private Placement Of Shares For US$2.8 Million 12
Protalex Raise USD1.4 Million in Private Placement of Notes Due 2023 13
Protalex Inc, Key Competitors 14
Protalex Inc, Key Employees 15

List of Figures
Protalex Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Protalex Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Protalex Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Protalex Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Protalex Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Protalex Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Protalex Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Protalex Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

★海外企業調査レポート[Protalex Inc (PRTX):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Storopack Hans Reichenecker GmbH:企業の戦略的SWOT分析
    Storopack Hans Reichenecker GmbH - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major pr …
  • Constantia Flexibles Group GmbH:企業の戦略的SWOT分析
    Constantia Flexibles Group GmbH - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major pro …
  • PharmaCyte Biotech Inc (PMCB):製薬・医療:M&Aディール及び事業提携情報
    Summary PharmaCyte Biotech Inc (PharmaCyte), formerly Nuvilex Inc, is a clinical stage biotechnology company that develops and commercializes treatments for cancer and diabetes. The company offers technology is used for the treatment of advanced and inoperable pancreatic cancer and diabetes. It deve …
  • Greene King Plc
    Greene King Plc - Strategy, SWOT and Corporate Finance Report Summary Greene King Plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpo …
  • SunPower Corporation:企業の戦略・SWOT・財務情報
    SunPower Corporation - Strategy, SWOT and Corporate Finance Report Summary SunPower Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings …
  • Globus Medical, Inc. (GMED)-医療機器分野:企業M&A・提携分析
    Summary Globus Medical, Inc. (Globus) is a medical device company which manufactures and markets musculoskeletal implants with focus on the treatment of spine disorders. The company’s product portfolio includes biomaterial products, cervical, deformity, intervertebral fusion, minimally invasive, mot …
  • Platte River Power Authority:企業の戦略的SWOT分析
    Platte River Power Authority - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major produc …
  • Biofuels Power Corp (BFLS):企業の財務・戦略的SWOT分析
    Summary Biofuels Power Corp (BFLS), is a renewable energy corporation that develops bio fuels. The corporation operates and develops grid-connected biodiesel power electric generation plants. It produces fuels through transesterification of off-spec oils and gasification of waste products such as gl …
  • Molecular Partners AG (MOLN):企業の財務・戦略的SWOT分析
    Summary Molecular Partners AG (Molecular Partners) is a clinical stage bio pharmaceutical company that develops biological drugs. The company offers advanced small protein therapies such as abicipar, a designed ankyrin repeat protein based anti-angiogenic drug developed for diabetic macular edema an …
  • Sinopharm Group Co Limited:企業の戦略・SWOT・財務分析
    Sinopharm Group Co Limited - Strategy, SWOT and Corporate Finance Report Summary Sinopharm Group Co Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and servi …
  • Itausa – Investimentos Itau SA (ITSA4):企業の財務・戦略的SWOT分析
    Itausa - Investimentos Itau SA (ITSA4) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths a …
  • RCS MediaGroup SpA (RCS):企業の財務・戦略的SWOT分析
    RCS MediaGroup SpA (RCS) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • BOC Aviation Limited (2588):企業の財務・戦略的SWOT分析
    BOC Aviation Limited (2588) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakness …
  • Intuitive Surgical Inc (ISRG)-医療機器分野:企業M&A・提携分析
    Summary Intuitive Surgical Inc (Intuitive Surgical) is a provider of robotic-assisted minimally invasive surgery (MIS) devices. Its portfolio encompasses da Vinci Surgical Systems, InSite and Firefly Fluorescence imaging systems (Firefly), instruments and accessories and training technologies. The c …
  • Jazz Pharmaceuticals Plc (JAZZ):製薬・医療:M&Aディール及び事業提携情報
    Summary Jazz Pharmaceuticals plc (Jazz Pharmaceuticals) is a specialty biopharmaceutical company which identifies, develops and commercializes medicines with focus on narcolepsy, cancer, pain and psychiatry. Its major marketed products include Xyrem, sodium oxybate oral solution, for the treatment o …
  • Kuwait Food Company (Americana) KSCP:企業の戦略的SWOT分析
    Kuwait Food Company (Americana) KSCP - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and majo …
  • Arab National Bank:企業の戦略・SWOT・財務分析
    Arab National Bank - Strategy, SWOT and Corporate Finance Report Summary Arab National Bank - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …
  • Editas Medicine Inc (EDIT):製薬・医療:M&Aディール及び事業提携情報
    Summary Editas Medicine Inc (Editas Medicine) formerly Gengine Inc, is a discovery stage biotechnology company that develops genome level treatments for rare diseases. The company is developing a proprietary genome editing platform based on its in-licensed clustered regularly interspaced short palin …
  • NovoCure Ltd (NVCR)-医療機器分野:企業M&A・提携分析
    Summary NovoCure Ltd (NovoCure) is an drug company that concentrates on the development and commercialization of novel therapies for tumor treating fields. The company’s pipeline products find application in various types of cancer indications such as ovarian cancer, malignant melanoma, hepatocellul …
  • C.A. Curtze Co. Inc.:企業の戦略・SWOT・財務分析
    C.A. Curtze Co. Inc. - Strategy, SWOT and Corporate Finance Report Summary C.A. Curtze Co. Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆